231 related articles for article (PubMed ID: 27247325)
21. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
22. Analysis of FLT3-ITD and FLT3-Asp835 mutations in de novo acute myeloid leukemia: evaluation of incidence, distribution pattern, correlation with cytogenetics and characterization of internal tandem duplication from Indian population.
Ahmad F; Mandava S; Das BR
Cancer Invest; 2010 Jan; 28(1):63-73. PubMed ID: 19995225
[TBL] [Abstract][Full Text] [Related]
23. [Clinical significance of FLT3 internal tandem duplication in acute myeloid leukemia with chromosome abnormality].
Wang J; Li S; Wang T
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):700-4. PubMed ID: 17708786
[TBL] [Abstract][Full Text] [Related]
24. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.
Rollins-Raval M; Pillai R; Warita K; Mitsuhashi-Warita T; Mehta R; Boyiadzis M; Djokic M; Kant JA; Roth CG
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):212-7. PubMed ID: 22914610
[TBL] [Abstract][Full Text] [Related]
25. Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.
Falk IJ; Fyrberg A; Paul E; Nahi H; Hermanson M; Rosenquist R; Höglund M; Palmqvist L; Stockelberg D; Wei Y; Gréen H; Lotfi K
Am J Hematol; 2013 Dec; 88(12):1001-6. PubMed ID: 23873772
[TBL] [Abstract][Full Text] [Related]
26. The role of cytogenetic abnormalities in acute myeloid leukemia with NPM1 mutations and no FLT3 internal tandem duplication.
Micol JB; Boissel N; Renneville A; Castaigne S; Gardin C; Preudhomme C; Dombret H
Blood; 2009 Nov; 114(20):4601-2; author reply 4602-3. PubMed ID: 19965707
[No Abstract] [Full Text] [Related]
27. FLT3 internal tandem duplication and FLT3-D835 mutation in 80 AML patients categorized into cytogenetic risk groups.
Mały E; Przyborsk M; Nowak T; Nowak J; Januszkiewicz D
Postepy Hig Med Dosw (Online); 2010 Oct; 64():466-70. PubMed ID: 20966504
[TBL] [Abstract][Full Text] [Related]
28. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.
Allen C; Hills RK; Lamb K; Evans C; Tinsley S; Sellar R; O'Brien M; Yin JL; Burnett AK; Linch DC; Gale RE
Leukemia; 2013 Sep; 27(9):1891-901. PubMed ID: 23783394
[TBL] [Abstract][Full Text] [Related]
29. FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation in tyrosine kinase domain of FLT3 gene from Western India.
Ghosh K; Swaminathan S; Madkaikar M; Gupta M; Kerketta L; Vundinti B
Ann Hematol; 2012 Nov; 91(11):1703-12. PubMed ID: 22733614
[TBL] [Abstract][Full Text] [Related]
30. CD34 expression on bone marrow blasts is a novel predictor of poor prognosis independent of FlT3-ITD in acute myeloid leukemia with the NPM1-mutation.
Zhu HH; Liu YR; Jiang H; Lu J; Qin YZ; Jiang Q; Bao L; Ruan GR; Jiang B; Huang X
Leuk Res; 2013 Jun; 37(6):624-30. PubMed ID: 23473998
[TBL] [Abstract][Full Text] [Related]
31. Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy.
Tiesmeier J; Müller-Tidow C; Westermann A; Czwalinna A; Hoffmann M; Krauter J; Heil G; Ganser A; Serve H; Verbeek W
Leuk Res; 2004 Oct; 28(10):1069-74. PubMed ID: 15289019
[TBL] [Abstract][Full Text] [Related]
32. [Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].
Qiao M; Li WY; Sun AN; Chen SN; Liang JY; Ding ZX; Feng YF; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):679-83. PubMed ID: 22339826
[TBL] [Abstract][Full Text] [Related]
33. [Correlation of FLT3 gene expression level and internal tandem duplication mutation in acute myeloid leukemia and its clinical significance].
Wang YG; Liu XH; Liang Y; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):741-5. PubMed ID: 19176010
[TBL] [Abstract][Full Text] [Related]
34. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.
Ribeiro AF; Pratcorona M; Erpelinck-Verschueren C; Rockova V; Sanders M; Abbas S; Figueroa ME; Zeilemaker A; Melnick A; Löwenberg B; Valk PJ; Delwel R
Blood; 2012 Jun; 119(24):5824-31. PubMed ID: 22490330
[TBL] [Abstract][Full Text] [Related]
35. Negative impact of FLT3-ITD mutation on expression of MDR-1 mRNA in adult acute myeloid leukemia.
Nasiłowska-Adamska B; Solarska I
Leuk Lymphoma; 2012 Dec; 53(12):2523-6. PubMed ID: 22591177
[No Abstract] [Full Text] [Related]
36. RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes.
Greif PA; Konstandin NP; Metzeler KH; Herold T; Pasalic Z; Ksienzyk B; Dufour A; Schneider F; Schneider S; Kakadia PM; Braess J; Sauerland MC; Berdel WE; Büchner T; Woermann BJ; Hiddemann W; Spiekermann K; Bohlander SK
Haematologica; 2012 Dec; 97(12):1909-15. PubMed ID: 22689681
[TBL] [Abstract][Full Text] [Related]
37. Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks.
Deneberg S; Guardiola P; Lennartsson A; Qu Y; Gaidzik V; Blanchet O; Karimi M; Bengtzén S; Nahi H; Uggla B; Tidefelt U; Höglund M; Paul C; Ekwall K; Döhner K; Lehmann S
Blood; 2011 Nov; 118(20):5573-82. PubMed ID: 21960591
[TBL] [Abstract][Full Text] [Related]
38. De novo acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): a clinicopathologic and cytogenetic study of an entity recently added to the WHO classification.
Sun J; Konoplev SN; Wang X; Cui W; Chen SS; Medeiros LJ; Lin P
Mod Pathol; 2011 Mar; 24(3):384-9. PubMed ID: 21113141
[TBL] [Abstract][Full Text] [Related]
39. CD30 expression in acute myeloid leukemia is associated with FLT3-internal tandem duplication mutation and leukocytosis.
Fathi AT; Preffer FI; Sadrzadeh H; Ballen KK; Amrein PC; Attar EC; McAfee SL; Dillon L; Chen YB; Hasserjian RP
Leuk Lymphoma; 2013 Apr; 54(4):860-3. PubMed ID: 22966913
[No Abstract] [Full Text] [Related]
40. Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
Becker H; Maharry K; Radmacher MD; Mrózek K; Metzeler KH; Whitman SP; Schwind S; Kohlschmidt J; Wu YZ; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Moore JO; Caligiuri MA; Larson RA; Marcucci G; Bloomfield CD
Haematologica; 2011 Oct; 96(10):1488-95. PubMed ID: 21659357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
